nach oben

Cancer Causes & Control

Erschienen in:

21.01.2019 | Original Paper

Body mass index modifies bladder cancer risk associated with low estrogen exposure among Egyptian women after menopause

verfasst von: Sania Amr, Beverly J. Wolpert, Diane Marie St. George, India James, Christopher A. Loffredo

Erschienen in: Cancer Causes & Control | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Investigators have reported inconsistent findings regarding associations between body mass index (BMI) and bladder cancer risk, and they have postulated that sex steroids mediate such associations. We assessed the impact of BMI on the relationship between bladder cancer risk and combinations of age at first childbirth, parity, and age at menopause, among Egyptian women.

Methods

We used data from our multicenter case–control study of 419 cases and 786 controls in logistic regression models to estimate adjusted odds ratios (AORs) and 95% confidence intervals (CIs) of such associations.

Results

Age > 18 years at first childbirth and parity ≤ 6 were significantly associated with bladder cancer risk, which was higher when both factors (AOR = 2.31, 95% CI = 1.55–3.43) and age at menopause < 45 years (AOR = 3.51, 95% CI = 1.88–6.55) were present. Early menopause was associated with higher bladder cancer risk in obese (AOR = 2.90, 95% CI = 1.40–5.98) but not normal weight women (AOR = 0.98, 95% CI = 0.58–1.65; P_interaction = 0.11), and the risk was greatest when both first childbirth at age > 18 years and parity ≤ 6 were present (AOR = 7.60, 95% CI = 1.84–31.35); however, overweight and obesity were associated with significantly lower bladder cancer risk (AOR = 0.59, 95% CI = 0.43–0.81, and AOR = 0.26, 95% CI = 0.18–0.38, respectively).

Conclusion

Body mass index appears to modify bladder cancer risk in Egyptian women after menopause by slightly enhancing the risk associated with low estrogen exposure among the obese only. Longitudinal studies of the BMI role in bladder malignancy in this distinctive population are required.

Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F (2017) Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol 71:96–108. https://doi.org/10.1016/j.eururo.2016.06.010 CrossRefPubMed

Miyamoto H, Yang Z, Chen YT, Ishiguro H, Uemura H, Kubota Y, Nagashima Y, Chang YJ, Hu YC, Tsai MY, Yeh S, Messing EM, Chang C (2007) Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst 99:558–568. https://doi.org/10.1016/j.eururo.2016.06.010 CrossRefPubMed

Zhang Y (2013) Understanding the gender disparity in bladder cancer risk: the impact of sex hormones and liver on bladder susceptibility to carcinogens. J Environ Sci Health Part C 31:287–304. https://doi.org/10.1080/10590501.2013.844755 CrossRef

McGrath M, Michaud DS, De Vivo I (2006) Hormonal and reproductive factors and the risk of bladder cancer in women. Am J Epidemiol 63:236–244. https://doi.org/10.1093/aje/kwj028 CrossRef

Prizment AE, Anderson KE, Harlow BL, Folsom AR (2007) Reproductive risk factors for incident bladder cancer: Iowa Women’s Health Study. Int J Cancer 120:1093–1098. https://doi.org/10.1002/ijc.22418 CrossRefPubMed

Wolpert BJ, Amr S, Ezzat S, Saleh DA, Gouda I, Loay I, Hifnawy T, Mikhail NN, Abdel-Hamid M, Zhan M, Zheng Y-L, Squibb K, Abdel-Aziz MA, Zaghloul M, Khaled H, Loffredo CA (2010) Estrogen exposure and bladder cancer risk in Egyptian women. Maturitas 67:353–357. https://doi.org/10.1016/j.maturitas.2010.07.014 CrossRefPubMedPubMedCentral

Daugherty SE, Lacey JV Jr, Pfeiffer RM, Park Y, Hoover RN, Silverman DT (2013) Reproductive factors and menopausal hormone therapy and bladder cancer risk in the NIH-AARP Diet and Health Study. Int J Cancer 133:462–472. https://doi.org/10.1002/ijc.28022 CrossRefPubMedPubMedCentral

Morales EE, Grill S, Svatek RS, Kaushik D, Thompson IM Jr, Ankerst DP, Liss MA (2016) Finasteride reduces risk of bladder cancer in a large prospective screening study. Eur Urol 69:407–410. https://doi.org/10.1016/j.eururo.2015.08.029 CrossRefPubMed

Weibull CE, Eloranta S, Altman D, Johansson AL, Lambe M (2013) Childbearing and the risk of bladder cancer: a nationwide population-based cohort study. Eur Urol 63:733–738. https://doi.org/10.1016/j.eururo.2013.01.005 CrossRefPubMed

10.

Chiu HF, Chen BK, Yang C (2016) Parity, age at first birth, and risk of death from bladder cancer: a population-based cohort study in Taiwan. Int J Environ Res Public Health 13:E1197. https://doi.org/10.3390/ijerph13121197 CrossRefPubMed

11.

Davis-Dao CA, Henderson KD, Sullivan-Halley J, Ma H, West D, Xiang YB, Gago-Dominguez M, Stern MC, Castelao JE, Conti DV, Pike MC, Bernstein L, Cortessis VK (2011) Lower risk in parous women suggests that hormonal factors are important in bladder cancer etiology. Cancer Epidemiol Biomarkers Prev 20:1156–1170. https://doi.org/10.1158/1055-9965.EPI-11-0017 CrossRefPubMedPubMedCentral

12.

Huang AT, Kogevinas M, Silverman DT, Malats N, Rothman N, Tardón A, Serra C, García-Closas R, Carrato A, Cantor KP (2009) Bladder cancer and reproductive factors among women in Spain. Cancer Causes Control 20:1907–1913. https://doi.org/10.1007/s10552-009-9384-1 CrossRefPubMedPubMedCentral

13.

De Ridder J, Julián-Almárcegui C, Mullee A, Rinaldi S, Van Herck K, Vicente-Rodríguez G, Huybrechts I (2016) Comparison of anthropometric measurements of adiposity in relation to cancer risk: a systematic review of prospective studies. Cancer Causes Control 27:291–300. https://doi.org/10.1007/s10552-015-0709-y CrossRefPubMed

14.

Noguchi JL, Liss MA, Parsons JK (2015) Obesity, physical activity and bladder cancer. Curr Urol Rep 16:74. https://doi.org/10.1007/s11934-015-0546-2 CrossRefPubMed

15.

Qin Q, Xu X, Wang X, Zheng XY (2013) Obesity and risk of bladder cancer: a meta-analysis of cohort studies. Asian Pac J Cancer Prev 14:3117–3121. https://doi.org/10.7314/APJCP.2013.14.5.3117 CrossRefPubMed

16.

Sun JW, Zhao LG, Yang Y, Ma X, Wang YY, Xiang YB (2015) Obesity and risk of bladder cancer: a dose-response meta-analysis of 15 cohort studies. PLoS ONE 10:e0119313. https://doi.org/10.1371/journal.pone.0119313 CrossRefPubMedPubMedCentral

17.

Häggström C, Stocks T, Rapp K, Bjørge T, Lindkvist B, Concin H, Engeland A, Manjer J, Ulmer H, Selmer R, Tretli S, Hallmans G, Jonsson H, Stattin P (2011) Metabolic syndrome and risk of bladder cancer: prospective cohort study in the metabolic syndrome and cancer project (Me-Can). Int J Cancer 128:1890–1898. https://doi.org/10.1002/ijc.25521 CrossRefPubMed

18.

Cantiello F, Cicione A, Salonia A, Autorino R, De Nunzio C, Briganti A, Gandaglia G, Dell’Oglio P, Capogrosso P, Damiano R (2015) Association between metabolic syndrome, obesity, diabetes mellitus and oncological outcomes of bladder cancer: a systematic review. Int J Urol 22:22–32. https://doi.org/10.1111/iju.12644 CrossRefPubMed

19.

Renehan AG, Tuson M, Egger M, Heller RF, Zwahlen M (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371:569–578. https://doi.org/10.1016/S0140-6736(08)60269-X CrossRef

20.

De Pergola G, Silvestris F (2013) Obesity as a major risk factor for cancer. J Obes 2013:291546. https://doi.org/10.1155/2013/291546 CrossRefPubMedPubMedCentral

21.

Dobruch J, Daneshmand S, Fisch M, Lotan Y, Noon AP, Resnick MJ, Shariat SF, Zlotta AR, Boorjian SA (2016) Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes. Eur Urol 69:300–310. https://doi.org/10.1016/j.eururo.2015.08.037 CrossRefPubMed

22.

Zheng YL, Amr S, Saleh DA, Dash C, Ezzat S, Mikhail NN, Gouda I, Loay I, Hifnawy T, Abdel-Hamid M, Khaled H, Wolpert B, Abdel-Aziz MA, Loffredo CA (2012) Urinary bladder cancer risk factors in Egypt: a multicenter case–control study. Cancer Epidemiol Biomarkers Prev 21:537–546. https://doi.org/10.1158/1055-9965.EPI-11-0589 CrossRefPubMed

23.

Zhao L, Tian X, Duan X, Ye Y, Sun M, Huang J (2017) Association of body mass index with bladder cancer risk: a dose-response meta-analysis of prospective cohort studies. Oncotarget 8:33990–34000. https://doi.org/10.18632/oncotarget.16722%5D CrossRefPubMedPubMedCentral

24.

Kershaw EE, Flier JS (2004) Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89:2548–2556. https://doi.org/10.1210/jc.2004-0395 CrossRefPubMed

25.

Tan W, Boorjian S, Advani P, Farmer S, Lohse C, Cheville J, Kwon E, Leibovich B (2015) The estrogen pathway: estrogen receptor-α, progesterone receptor, and estrogen receptor-β expression in radical cystectomy urothelial cell carcinoma specimens. Clin Genitourin Cancer 13:476–484. https://doi.org/10.1016/j.clgc.2015.04.001 CrossRefPubMed

26.

Miyamoto H, Yao JL, Chaux A, Zheng Y, Hsu I, Izumi K, Chang C, Messing EM, Netto GJ, Yeh S (2012) Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder. BJU Int 109:1716–1726. https://doi.org/10.1111/j.1464-410X.2011.10706.x CrossRefPubMed

27.

Randolph JF Jr, Sowers MF, Bondarenko IV, Harlow SD, Luborsky JL, Little RJ (2004) Change in estradiol and follicle-stimulating hormone across the early menopausal transition: effects of ethnicity and age. J Clin Endocrinol Metab 89:1555–1561. https://doi.org/10.1210/jc.2003-031183 CrossRefPubMed

28.

Simpson ER, Misso M, Hewitt KN, Hill RA, Boon WC, Jones ME, Kovacic A, Zhou J, Clyne CD (2006) Estrogen—the good, the bad, and the unexpected. Endocr Rev 26:322–330. https://doi.org/10.1210/er.2004-0020 CrossRef

29.

Warner ET, Hu R, Collins LC, Beck AH, Schnitt S, Rosner B, Eliassen AH, Michels KB, Willett WC, Tamimi RM (2016) Height and body size in childhood, adolescence, and young adulthood and breast cancer risk according to molecular subtype in the Nurses’ Health Studies. Cancer Prev Res 9:732–738. https://doi.org/10.1158/1940-6207.CAPR-16-0085 CrossRef

30.

The Premenopausal Breast Cancer Collaborative Group (2018) Association of body mass index and age with subsequent breast cancer risk in premenopausal women. JAMA Oncol https://doi.org/10.1001/jamaoncol.2018.1771 CrossRefPubMedCentral

Titel: Body mass index modifies bladder cancer risk associated with low estrogen exposure among Egyptian women after menopause
verfasst von: Sania Amr
Beverly J. Wolpert
Diane Marie St. George
India James
Christopher A. Loffredo
Publikationsdatum: 21.01.2019
Verlag: Springer International Publishing
Erschienen in: Cancer Causes & Control / Ausgabe 3/2019
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-019-1131-7

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Body mass index modifies bladder cancer risk associated with low estrogen exposure among Egyptian women after menopause

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2019

First-year weight loss with androgen-deprivation therapy increases risks of prostate cancer progression and prostate cancer-specific mortality: results from SEARCH

Racial disparities in eligibility for low-dose computed tomography lung cancer screening among older adults with a history of smoking

Randomized trial of a web-based survivor intervention on melanoma prevention behaviors of first-degree relatives

Food insecure cancer survivors continue to smoke after their diagnosis despite not having enough to eat: implications for policy and clinical interventions

Epidemiological trends of oropharyngeal and oral cavity squamous cell carcinomas in Northern New England, 2000–2013

Prevalence and correlates of dual tobacco use in cancer survivors

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie